Latest Breaking News On - Suspected prostate cancer recurrence - Page 2 : comparemela.com

Blue Earth Diagnostics Highlights Presentations on POSLUMA® (Flotufolastat F 18) in Prostate Cancer at Upcoming 2024 ASCO Genitourinary Cancers Symposium (ASCO GU)

Blue Earth Diagnostics Highlights Presentations on POSLUMA® (Flotufolastat F 18) in Prostate Cancer at Upcoming 2024 ASCO Genitourinary Cancers Symposium (ASCO GU)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesWest hallSanta monicaSan franciscoUnited kingdomPriscilla harlanZachariah taylorPrzemyslaw twardowskiDavide gaudenBenjaminh lowentrittClare gidleyMike beyerGeorger moscone convention centerMain line healthBlue earth diagnostics ltdBracco group

Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

Sub-group analysis from Blue Earth Diagnostics’ Phase 3 LIGHTHOUSE trial highlights POSLUMA utility to guide treatment selection and potentially avoid futile surgery

Davide gaudenGarya ulanerScintomics gmbPhilliph kuoLos angelesUniversity of arizonaStudy groupDrug administrationUniversity of southern californiaSolutions incHoag family cancer instituteTechnical university of munichA siemens healthineers companyBlue earth diagnosticsTrue positiveDetection rate

New Data on POSLUMA® (Flotufolastat F 18) in Patients with Suspected Biochemical Recurrence of Prostate Cancer and Low-Very Low Prostate Specific Antigen (PSA) Levels Presented at ASTRO

New Data on POSLUMA® (Flotufolastat F 18) in Patients with Suspected Biochemical Recurrence of Prostate Cancer and Low-Very Low Prostate Specific Antigen (PSA) Levels Presented at ASTRO
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomClare gidleyMike beyerDavide gaudenScintomics gmbAsheshb janiPriscilla harlanSam brown incStudy groupCorporate communicationsNuclear medicineWinship cancer institute of emory universitySolutions incBracco groupTechnical university of munichA siemens healthineers company

New Data on POSLUMA® (Flotufolastat F 18) in Patients with Suspected Biochemical Recurrence of Prost

− Post-hoc analysis from Blue Earth Diagnostics’ Phase 3 SPOTLIGHT trial provides data about treatment planning, particularly when curative salvage therapy is considered –For U.S audiences onlyMONROE TOWNSHIP, N.J. & OXFORD, England (BUSINESS WIRE) Blue Earth Diagnostics, a Bracco company and recognized leader in.

United kingdomScintomics gmbClare gidleyPriscilla harlanAsheshb janiMike beyerStudy groupSam brown incDrug administrationBracco groupTechnical university of munichNuclear medicineWinship cancer institute of emory universityCorporate communicationsBlue earth diagnostic phaseBlue earth diagnostics

Additional Results of POSLUMA® (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

Additional Results of POSLUMA® (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomDavide gaudenGarya ulanerClare gidleyPriscilla harlanPhilliph kuoLos angelesScintomics gmbMike beyerUniversity of arizonaDrug administrationHoag family cancer instituteTechnical university of munichBracco groupA siemens healthineers companyStudy group